• Cy5.5 NHS Ester (Non-Sulfonated): Precision Fluorescent Labe

  2026-04-25

  Explore the scientific principles and practical protocols behind Cy5.5 NHS ester (non-sulfonated) for near-infrared biomolecule labeling. This article reveals new insights into optimizing fluorescence imaging, highlights recent polysaccharide distribution studies, and uniquely guides advanced assay design.

• Diphenyleneiodonium Chloride: Optimizing Redox and cAMP Assa

  2026-04-24

  Diphenyleneiodonium chloride (DPI) is a cornerstone for probing redox enzyme activity and cAMP signaling, enabling precise dissection of oxidative stress responses and signal modulation. Here, we deliver a workflow-driven guide on leveraging DPI for robust experimental outcomes, including expert troubleshooting and protocol enhancements grounded in evidence.

• Clinical and Biochemical Roles of Ademetionine in CNS Disord

  2026-04-24

  This review by Bottiglieri et al. systematically explores the role of Ademetionine (S-adenosylmethionine; SAMe) in methylation-dependent neurobiological processes and its therapeutic potential in central nervous system (CNS) disorders. The article highlights mechanistic insights linking methyl donor deficiency to neuropsychiatric disease and synthesizes early clinical evidence for SAMe in treating depression and dementia.

• PLGA-Based Nano-Adjuvant Boosts Mucosal and Systemic Immunit

  2026-04-23

  This study introduces a novel PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) that significantly augments both mucosal and systemic immune responses in chicks vaccinated against H9N2 avian influenza. By enhancing intestinal targeting and IgA production, the approach addresses limitations of current vaccine adjuvants and demonstrates a promising strategy for improved avian disease control.

• Nonivamide (Capsaicin Analog): Precision TRPV1 Agonism in Ca

  2026-04-23

  Explore Nonivamide, a selective capsaicin analog, as a tool for dissecting TRPV1-mediated anti-inflammatory and anti-cancer pathways. This article uniquely bridges molecular pharmacology with translational assay design and highlights findings from recent TRPV1 neuroimmune research.

• Cyclophosphamide: Alkylating Chemotherapeutic Agent for Rese

  2026-04-22

  Cyclophosphamide is a clinically validated alkylating chemotherapeutic agent that induces DNA cross-linking and apoptosis in proliferating cells. Its broad utility spans cancer research, bone marrow transplantation conditioning, and autoimmune disease models. Protocols and evidence-backed parameters enable reproducible apoptosis induction and immune modulation in preclinical workflows.

• Cy5 maleimide (non-sulfonated): Technical Guide for Protein

  2026-04-22

  Cy5 maleimide (non-sulfonated) addresses the need for site-specific, efficient fluorescent labeling of proteins and peptides containing accessible thiol groups, especially cysteine residues. It is not suitable for targets lacking free thiols or workflows demanding aqueous-only labeling conditions.

• Cholesterol Impairs Lipid Nanoparticle Trafficking for RNA D

  2026-04-21

  This study demonstrates that increasing cholesterol content in lipid nanoparticles (LNPs) hinders their intracellular trafficking by promoting aggregation in peripheral early endosomes, thereby reducing nucleic acid delivery efficiency. The findings provide critical guidance for optimizing LNP composition in RNA delivery applications and highlight the importance of careful cholesterol balancing in therapeutic formulations.

• Dual-Immunoregulatory mRNA Nanovaccine for RA and Pneumonia

  2026-04-21

  This study introduces a dual-action mRNA nanovaccine that simultaneously targets rheumatoid arthritis (RA) and its associated pneumonia through coordinated immune modulation. The research provides a new platform for treating autoimmune disorders with extra-articular complications, demonstrating robust in vivo distribution and immunoregulatory efficacy.

• PAD4-IN-2 TFA: Applied Workflows in Tumor Microenvironment R

  2026-04-20

  PAD4-IN-2 TFA empowers tumor biology researchers with precise, highly selective PAD4 inhibition, featuring targeted cellular uptake and robust in vivo antitumor performance. Its meta-phenylboronic acid modification and outstanding safety profile distinguish it for advanced studies on neutrophil extracellular traps (NETs) and tumor immune modulation.

• Z-YVAD-FMK: Precision Caspase-1 Inhibition for Translational

  2026-04-20

  Explore Z-YVAD-FMK, a leading caspase-1 inhibitor, in the context of apoptosis, pyroptosis, and emerging cell death modalities. This article uniquely connects precise caspase targeting to advanced cancer and inflammasome research, offering deeper protocol insight and practical guidance.

• Plerixafor (AMD3100): Bridging Mechanism to Translation in C

  2026-04-19

  This thought-leadership article delivers mechanistic insights and strategic guidance for translational researchers using Plerixafor (AMD3100) in CXCR4-driven cancer, stem cell, and immunology studies. Leveraging the latest comparative data and workflow expertise, it addresses the evolving landscape of CXCR4 antagonists and outlines best practices for robust, reproducible experimentation.

• Naloxone Hydrochloride: Advancing Opioid Receptor Antagonist

  2026-04-18

  Naloxone hydrochloride from APExBIO offers scientists a high-purity, reproducible tool for dissecting opioid receptor signaling and neural stem cell modulation. This article translates bench evidence into actionable workflows, with troubleshooting tips and protocol parameters for cutting-edge addiction and neurobiology research.

• Ornithine–ZBTB7A Axis in Realgar-Induced CNS Toxicity: New M

  2026-04-17

  This study uncovers how realgar-derived arsenic disrupts astrocyte glycolysis through an ornithine–ZBTB7A pathway, linking hepatic urea cycle dysfunction to central nervous system toxicity. These mechanistic insights offer targeted avenues for future neurotoxicity and metabolic research.

• PLGA-Based Nano-Adjuvant Enhances Mucosal Immunity in Chicks

  2026-04-16

  This study introduces a novel PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) designed to improve mucosal and systemic immunity against H9N2 avian influenza in chicks. By targeting the intestinal tract and promoting IgA production, the formulation addresses key limitations of current vaccine adjuvants and provides actionable insights for optimizing vaccine efficacy.

16428 records 1/1096 page Next 12345 下5页 Last page